Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906497 · ClinicalTrials.gov registry record · Phase 4
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by Johann E Gudjonsson MD PhD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06906497: Recruiting Phase 4 study of Atopic Dermatitis, sponsored by Johann E Gudjonsson MD PhD.
NCT06906497 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Johann E Gudjonsson MD PhD. The registered enrollment target is 48 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906497, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Johann E Gudjonsson MD PhD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Primary Outcome
Assessed from skin biopsies using the molecular response to lebrikizumab among patients with atopic dermatitis
Conditions Studied
Interventions
- DRUG lebrikizumab
Study Locations (4)
Other
- University of Freiburg - Freiburg im Breisgau
- Lausanne University Hospital - Lausanne
California
- Physioseq USA - CA - Folsom
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
What NCT06906497 shows while recruiting
NCT06906497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which lebrikizumab is the first listed.
NCT06906497 reports a single indexed study location in Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06906497 about?
NCT06906497 is a clinical study titled "Lebrikizumab in Moderate-to-severe Atopic Dermatitis". This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
What is the current status of trial NCT06906497?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2025-07-02. Estimated completion is 2027-07.
What conditions does trial NCT06906497 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06906497?
The interventions under investigation include: lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT06906497?
This trial is sponsored by Johann E Gudjonsson MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906497 being conducted?
This trial has 4 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906497's enrollment target sits among peer trials
48 110th of 150 higher than 41 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI